IL6 and breast carcinoma: Since IL-6 exerts its influence on breast cancer cells via JAK2/STAT3 pathway, the inhibitory effect of Nar-Cpm combination on IL-6 influence further proves its ability to target JAK2/STAT3 signaling pathway.